Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
VanEck Semiconductor ETF
SMH
The Technology Select Sector SPDR® Fund
XLK
4
Invesco Solar ETF
TAN
5
Invesco DB Commodity Index Tracking Fund
DBC
US Stock MarketDetailed Quotes
Alterity Therapeutics (ATHE)
- 4.830
- +0.030+0.63%
Close May 12 15:59 ET
- 4.550
- -0.280-5.80%
Post 17:52 ET
87.55MMarket Cap-7.94P/E (TTM)
4.840High4.700Low11.29KVolume4.720Open4.800Prev Close53.32KTurnover0.08%Turnover RatioLossP/E (Static)18.13MShares7.00052wk High2.23P/B66.91MFloat Cap2.66052wk Low--Dividend TTM13.85MShs Float51.500Historical High--Div Yield TTM2.92%Range %1.001Historical Low4.722Avg Price1Lot Size
ATHE Stock Chart
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
ATHE Orderflow
Unit: --
ATHE Orderflow Trend
IntradayDayWeekMonth
No Data
Alterity Therapeutics (ATHE) News
Alterity Therapeutics Files May 2026 Form 6-K, Releases New Corporate Presentation
Alterity Therapeutics Announces Publication Of Peer-Reviewed Study In NeuroImage Showing QSM MRI Can Detect Disease-Specific Iron Accumulation In Brains Of Patients With MSA
Alterity Therapeutics Highlights MRI Biomarker Breakthrough as It Prepares Phase 3 MSA Program
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
Maxim Group Maintains Alterity Therapeutics(ATHE.US) With Buy Rating, Maintains Target Price $12
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Alterity Therapeutics (ATHE) and Moderna (MRNA)
Alterity Therapeutics (ATHE) Stock Forum
$Alterity Therapeutics (ATHE.US)$ need a push above 5$
$Alterity Therapeutics (ATHE.US)$
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
by Globe Newswire
Follow
– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in patients with Multiple System Atrophy (MSA) –
– Findings support QSM as an objective imaging biomarker ...
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
by Globe Newswire
Follow
– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in patients with Multiple System Atrophy (MSA) –
– Findings support QSM as an objective imaging biomarker ...
$Alterity Therapeutics (ATHE.US)$ Alterity Therapeutics Receives Positive FDA Feedback Following A Type C Meeting Regarding Its Planned Phase 3 Development Program For ATH434 In Multiple System Atrophy, A Rare, Rapidly Progressive Neurodegenerative Disease With No Approved...
Benzinga
1m
Alterity Therapeutics Receives Positive FDA Feedback Following A Type C Meeting Regarding Its Planned Phase 3 Development Program For ATH434 In Multiple System Atrophy, A Rare, Rapidly Progressive Neurodegene...
Benzinga
1m
Alterity Therapeutics Receives Positive FDA Feedback Following A Type C Meeting Regarding Its Planned Phase 3 Development Program For ATH434 In Multiple System Atrophy, A Rare, Rapidly Progressive Neurodegene...
$Alterity Therapeutics (ATHE.US)$ Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in
Late Breaking Science Session of the American Academy of Neurology
- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale -
- Effects seen on both daily function and neurological examination, consistent with previously reported activity on modified UMSARS Part I -
- Presentation reinforces ATH434's clinical profile ahead of ...
Late Breaking Science Session of the American Academy of Neurology
- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale -
- Effects seen on both daily function and neurological examination, consistent with previously reported activity on modified UMSARS Part I -
- Presentation reinforces ATH434's clinical profile ahead of ...
1
$Alterity Therapeutics (ATHE.US)$ will deliver an oral presentation during a Late Breaking Session at the American Academy of Neurology (AAN) Annual Meeting taking place April 21 in Chicago, IL, USA.
1
5
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)